Haemophilia A without inhibitors – Diagnostics – Overview of Information and Clinical Research

Diagnosing Haemophilia A without inhibitors is a journey that begins with recognizing unusual bleeding patterns and moves through specialized blood tests that measure how well clotting factors work in your body. Understanding when and why these tests happen can help you or your loved ones feel more prepared and less anxious about the process.

Introduction: Who Should Seek Diagnostic Testing

If you notice that bleeding lasts longer than it should after a minor cut, or if bruises appear easily and seem unusually large, these might be early signs that something is affecting how your blood clots. People who should consider seeking diagnostic testing for Haemophilia A include those who experience prolonged bleeding that is difficult to stop, especially after injuries or surgical procedures.^[2]

The condition often first becomes noticeable in infants, particularly when a baby boy is circumcised and the bleeding continues longer than expected. Other bleeding problems typically show up when a baby starts crawling and walking, as minor bumps and falls can lead to significant bruising or bleeding into joints.^[2] However, mild cases of Haemophilia A may go completely unnoticed until much later in life, sometimes not appearing until after surgery or a significant injury reveals the bleeding problem.

Family history plays an important role in deciding who should undergo testing. Since Haemophilia A is an inherited condition that passes through families, anyone with a family history of bleeding disorders should inform their healthcare provider. Women who carry the variant gene may not show symptoms themselves but can pass the condition to their children. Boys born to mothers who carry the gene have a 50 percent chance of having Haemophilia A, while daughters have a 50 percent chance of becoming carriers.^[2]

It is advisable to seek diagnostic testing if you or your child experiences any of the following: bleeding into joints that causes pain and swelling, blood in the urine or stool, frequent nosebleeds that are hard to stop, or bleeding that starts without any obvious cause. Sometimes gastrointestinal tract and urinary tract bleeding can occur, which are serious signs that require immediate medical attention.^[2]

⚠️ Important

If someone in your family has Haemophilia A, it is crucial that you undergo testing even if you do not currently show symptoms. Early diagnosis allows for better planning and management of the condition. Women who are carriers may have lower than usual quantities of Factor VIII and should be aware of this, especially before surgeries or childbirth.

Standard Diagnostic Methods

Diagnosing Haemophilia A requires a series of specialized blood tests that measure how well your blood clots and identify which clotting factor is missing or not working properly. The process usually begins when a healthcare provider suspects a bleeding disorder based on symptoms or family history.

If you are the first person in your family to have a suspected bleeding disorder, your healthcare provider will order what is called a coagulation study, which is a series of tests designed to understand how your blood clotting system functions. Once the specific genetic variant has been identified in one family member, other people in the family will need similar tests to diagnose whether they also have the condition or are carriers.^[2]

The primary laboratory tests used to diagnose Haemophilia A include several different measurements. The Partial Thromboplastin Time, often abbreviated as PTT, measures how long it takes for your blood to clot. This test looks at the time it takes for a clot to form after certain substances are added to your blood sample in a laboratory. People with Haemophilia A typically have a prolonged PTT, meaning their blood takes longer than normal to clot.

Another important test is the Prothrombin Time, or PT, which also measures clotting time but looks at a different part of the clotting system. In Haemophilia A, the PT is usually normal because the condition specifically affects Factor VIII, which is not measured by this particular test.^[2]

The most specific and important test for diagnosing Haemophilia A is the serum factor VIII activity test. This test directly measures how much Factor VIII is present in your blood and how well it is working. Factor VIII is one of the special proteins, called clotting factors, that your body needs to form blood clots properly. The result of this test determines not only whether you have Haemophilia A but also how severe your condition is.^[2]

The severity of Haemophilia A is classified based on the level of Factor VIII activity found in the blood. People with severe Haemophilia A have less than one percent of normal Factor VIII activity, those with moderate Haemophilia A have between one and five percent, and individuals with mild Haemophilia A have between five and forty percent of normal Factor VIII activity. Understanding the severity helps doctors predict how often bleeding might occur and plan the most appropriate treatment approach.

Healthcare providers also look for what are called inhibitors, which are antibodies that the body’s immune system creates against Factor VIII. When someone has inhibitors, their body attacks the Factor VIII used in treatment, making it less effective. Testing for inhibitors involves specialized blood tests that check whether these antibodies are present. This is particularly important because the presence of inhibitors changes how treatment must be given.^[2]

For women who may be carriers of the Haemophilia A gene, carrier testing can be performed through genetic testing or by measuring Factor VIII levels. Carriers may have Factor VIII levels that are lower than normal but higher than those seen in people with the full disease. Knowing carrier status is especially important for family planning and helps women understand their own bleeding risks during surgeries or childbirth.

Before birth, if there is a known family history of Haemophilia A, pregnant women may choose to have prenatal testing to determine if their baby will have the condition. This can be done through procedures such as chorionic villus sampling or amniocentesis, which collect cells from the developing baby for genetic testing. These tests carry some risks and are typically discussed carefully with a genetic counselor and healthcare provider.

Diagnostics for Clinical Trial Qualification

When researchers develop new treatments for Haemophilia A, they conduct clinical trials to test whether these treatments are safe and effective. To participate in these studies, patients must undergo specific diagnostic tests that help researchers ensure they are enrolling the right participants and can accurately measure how well the new treatment works.

The most fundamental requirement for enrolling in a clinical trial for Haemophilia A without inhibitors is documented proof of the diagnosis. This means having laboratory test results that confirm low levels of Factor VIII and show that the PTT is prolonged while the PT remains normal. Researchers need to see these documented results from previous testing to confirm that a person truly has Haemophilia A before they can join a trial.^[2]

Clinical trials typically require baseline measurements of Factor VIII activity levels. These measurements establish a starting point so that researchers can later compare how Factor VIII levels change after treatment begins. The specific Factor VIII level required may vary depending on the trial; some studies focus on people with severe Haemophilia A, while others may include those with moderate or mild forms of the condition.

A critical diagnostic test for clinical trial enrollment is inhibitor testing. Most trials for Haemophilia A without inhibitors specifically require that participants test negative for inhibitors, meaning their immune system has not created antibodies against Factor VIII. This is tested using specialized blood work that detects and measures these antibodies. Researchers must know that participants do not have inhibitors because the presence of inhibitors would affect how the body responds to treatment and would confuse the study results.

Beyond these basic blood tests, clinical trials often require what is called a comprehensive bleeding assessment. This involves documenting the participant’s bleeding history, including how many bleeding episodes they have experienced in the past year, which joints have been affected by bleeding, and whether they have any permanent joint damage from previous bleeds. Some trials use questionnaires or diaries where participants record every bleeding episode for several months before the trial begins.

Imaging studies may also be part of the qualification process for certain clinical trials, particularly those studying treatments aimed at preventing joint damage. Radiography, which means X-rays, or Magnetic Resonance Imaging, also known as MRI, might be performed on joints to assess any existing damage from previous bleeding. These images help researchers understand the current state of joint health and measure whether the new treatment prevents further damage over time.

⚠️ Important

Clinical trials often exclude people who have certain other medical conditions or who take specific medications that could interfere with study results. Your healthcare provider at a hemophilia treatment center can help you understand which trials might be appropriate for you and guide you through the qualification process. Not qualifying for one trial does not mean you cannot participate in others, as each study has different requirements.

Laboratory monitoring during the qualification period may include general health assessments such as complete blood counts, liver function tests, and kidney function tests. These ensure that participants are healthy enough to safely participate in the trial and that researchers can detect any potential side effects from the experimental treatment. Some trials also require testing for infectious diseases to ensure the safety of all participants and study staff.

For trials studying prophylactic treatments, which are treatments given regularly to prevent bleeding rather than to stop bleeding after it starts, researchers may require documentation of a participant’s current treatment regimen. This includes detailed records of how often Factor VIII concentrates are given, at what doses, and whether this treatment is given at home or at a medical facility. Understanding current treatment patterns helps researchers design trials that test whether new approaches are better than existing ones.

Genetic testing may be required for some clinical trials, particularly those studying gene therapy or other innovative treatments that work differently depending on the specific genetic variant causing Haemophilia A. These tests identify the exact mutation in the Factor VIII gene, which can influence whether a person is likely to respond to certain experimental treatments.

Prognosis and Survival Rate

Prognosis

The outlook for people living with Haemophilia A has improved dramatically over the past several decades thanks to advances in treatment. With proper treatment, most people with Haemophilia A are able to lead fairly normal lives.^[2] The prognosis depends largely on several important factors including the severity of the condition, how early treatment begins, and how consistently treatment is followed.

People with severe Haemophilia A who receive regular preventive treatment, known as prophylaxis, have significantly better long-term outcomes than those who only receive treatment when bleeding occurs. Prophylaxis has been shown to prevent or at least reduce the progression of damage to joints, which are common sites of bleeding in Haemophilia A. Starting prophylaxis early in childhood can prevent much of the joint deterioration that was common before these preventive treatments became available.^[6]

Research has demonstrated that people with Haemophilia A who receive care at comprehensive hemophilia treatment centers have better access to care, experience less illness and disability related to their condition, and have better overall health outcomes. Studies involving thousands of people with Haemophilia found that those receiving care at these specialized centers were forty percent less likely to die from complications related to their condition compared to those not getting care at such centers.^[6]

The development of inhibitors, which are antibodies that attack Factor VIII, can worsen the prognosis because these make standard treatment less effective. However, even when inhibitors develop, newer treatment options are available that can help manage bleeding and maintain quality of life. The key to a good prognosis is early diagnosis, consistent treatment, regular monitoring, and working closely with a team of healthcare specialists who understand the condition.

Most people with Haemophilia A can participate in many normal activities, attend school or work regularly, and form meaningful relationships. However, achieving the best possible outcomes requires commitment to treatment plans, prompt attention to bleeding episodes, and taking steps to prevent injuries that could cause bleeding.

Survival rate

With the treatments available today, life expectancy for people with Haemophilia A has improved significantly and continues to approach that of the general population. In well-resourced countries with access to modern clotting factor concentrates and comprehensive care, many people with Haemophilia A can expect to live into their sixties, seventies, and beyond, which represents a dramatic improvement from previous generations.

The survival rate has been transformed by several key developments in care. Before modern treatments became available in the 1970s, many people with severe Haemophilia A died young from uncontrolled bleeding. The introduction of clotting factor concentrates revolutionized care, though the contamination of some early blood products with HIV and hepatitis viruses in the 1980s tragically shortened the lives of many people with Haemophilia. Today, both plasma-derived and recombinant factor concentrates go through rigorous safety processes to eliminate any risk of transmitting bloodborne viruses.^[12]

Current survival depends heavily on the quality and consistency of care received. People with Haemophilia A who follow prophylactic treatment regimens, receive regular comprehensive checkups, and have prompt access to treatment for bleeding episodes have survival rates that closely mirror those of people without the condition. Studies have shown that those who receive care at hemophilia treatment centers have significantly better survival outcomes compared to those who do not have access to specialized care.

The severity of Haemophilia A also influences survival. Those with mild cases may never experience life-threatening bleeding and typically have normal life expectancy. People with moderate or severe Haemophilia A face greater risks, particularly from bleeding in the head or brain, internal bleeding, or complications from repeated joint bleeds, but with proper treatment and monitoring, most can avoid these serious complications and live long, healthy lives.

#1 Clinical Trials Search in Europe